BioXcel Therapeutics, Inc. Operating Expenses
BioXcel Therapeutics, Inc. (BTAI) reported Operating Expenses of $36.29 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2022-08-11
- BioXcel Therapeutics, Inc. operating expenses for the quarter ending 2022-06-30 was $36.29M, a 31.42% increase year-over-year.
- BioXcel Therapeutics, Inc. operating expenses for the quarter ending 2022-03-31 was $31.48M, a 19.34% increase year-over-year.
- BioXcel Therapeutics, Inc. operating expenses for the quarter ending 2021-12-31 was $26.13M, a 23.86% increase year-over-year.
- BioXcel Therapeutics, Inc. operating expenses for the quarter ending 2021-09-30 was $26.81M, a 8.25% increase year-over-year.
- BioXcel Therapeutics, Inc. operating expenses for fiscal 2021 was $106.94M, a 29.94% increase from fiscal 2020.
- BioXcel Therapeutics, Inc. operating expenses for fiscal 2020 was $82.30M, a 144.92% increase from fiscal 2019.
- BioXcel Therapeutics, Inc. operating expenses for fiscal 2019 was $33.60M, a 68.32% increase from fiscal 2018.
- BioXcel Therapeutics, Inc. operating expenses for fiscal 2018 was $19.96M, a 339.98% increase from fiscal 2017.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2022-06-30 | $36.29M 10-Q · filed 2022-08-11 | $67.77M 10-Q · filed 2022-08-11 | $93.90M derived: sum of 3 quarters · filed 2022-08-11 | $120.71M derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | $31.48M 10-Q · filed 2022-05-09 | $57.61M derived: sum of 2 quarters · filed 2022-05-09 | $84.42M derived: sum of 3 quarters · filed 2022-05-09 | $112.04M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-12-31 | $26.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $52.94M derived: sum of 2 quarters · filed 2022-03-11 | $80.56M derived: sum of 3 quarters · filed 2022-08-11 | $106.94M 10-K · filed 2022-03-11 |
| 2021-09-30 | $26.81M 10-Q · filed 2021-11-10 | $54.42M derived: sum of 2 quarters · filed 2022-08-11 | $80.80M 10-Q · filed 2021-11-10 | $101.90M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $27.61M 10-Q · filed 2022-08-11 | $53.99M 10-Q · filed 2022-08-11 | $75.09M derived: sum of 3 quarters · filed 2022-08-11 | $99.86M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $26.38M 10-Q · filed 2022-05-09 | $47.48M derived: sum of 2 quarters · filed 2022-05-09 | $72.24M derived: sum of 3 quarters · filed 2022-05-09 | $93.68M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $21.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $45.87M derived: sum of 2 quarters · filed 2022-03-11 | $67.30M derived: sum of 3 quarters · filed 2022-03-11 | $82.30M 10-K · filed 2022-03-11 |
| 2020-09-30 | $24.77M 10-Q · filed 2021-11-10 | $46.20M derived: sum of 2 quarters · filed 2021-11-10 | $61.20M 10-Q · filed 2021-11-10 | $69.61M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $21.43M 10-Q · filed 2021-08-10 | $36.43M 10-Q · filed 2021-08-10 | $44.84M derived: sum of 3 quarters · filed 2021-08-10 | $53.98M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $15.00M 10-Q · filed 2021-05-10 | $23.41M derived: sum of 2 quarters · filed 2021-05-10 | $32.54M derived: sum of 3 quarters · filed 2021-05-10 | $41.18M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $17.55M derived: sum of 2 quarters · filed 2021-03-12 | $26.18M derived: sum of 3 quarters · filed 2021-03-12 | $33.60M 10-K · filed 2021-03-12 |
| 2019-09-30 | $9.13M 10-Q · filed 2020-11-12 | $17.77M derived: sum of 2 quarters · filed 2020-11-12 | $25.19M 10-Q · filed 2020-11-12 | $32.50M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $8.63M 10-Q · filed 2020-08-14 | $16.05M 10-Q · filed 2020-08-14 | $23.37M derived: sum of 3 quarters · filed 2020-08-14 | $28.49M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $7.42M 10-Q · filed 2020-05-12 | $14.73M derived: sum of 2 quarters · filed 2020-05-12 | $19.85M derived: sum of 3 quarters · filed 2020-05-12 | $23.09M derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | $7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $12.43M derived: sum of 2 quarters · filed 2020-03-09 | $15.68M derived: sum of 3 quarters · filed 2020-03-09 | $19.96M 10-K · filed 2020-03-09 |
| 2018-09-30 | $5.12M 10-Q · filed 2019-11-14 | $8.36M derived: sum of 2 quarters · filed 2019-11-14 | $12.65M 10-Q · filed 2019-11-14 | $15.18M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $3.24M 10-Q · filed 2019-08-06 | $7.53M 10-Q · filed 2019-08-06 | $10.06M derived: sum of 3 quarters · filed 2019-08-06 | $10.97M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $4.29M 10-Q · filed 2019-05-07 | $6.81M derived: sum of 2 quarters · filed 2019-05-07 | $7.73M derived: sum of 3 quarters · filed 2019-05-07 | $8.29M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $3.44M derived: sum of 2 quarters · filed 2019-03-12 | $4.01M derived: sum of 3 quarters · filed 2019-03-12 | $4.54M 10-K · filed 2019-03-12 |
| 2017-09-30 | $917.00K 10-Q · filed 2018-11-09 | $1.48M derived: sum of 2 quarters · filed 2018-11-09 | $2.01M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $565.00K 10-Q · filed 2018-08-08 | $1.09M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |